Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;8(2):390-396.
doi: 10.1177/1932296814525826. Epub 2014 Mar 13.

Current Trends in Continuous Glucose Monitoring

Volker Lodwig  1 , Bernhard Kulzer  2 , Oliver Schnell  3 , Lutz Heinemann  4
Affiliations
Review

Current Trends in Continuous Glucose Monitoring

Volker Lodwig et al. J Diabetes Sci Technol. 2014 Mar.

Abstract

The market introduction of systems for continuous glucose monitoring (CGM) some 15 years ago did not immediately revolutionize the treatment of diabetes; however, for a given group of patients, it would almost be inconceivable nowadays to imagine life without CGM. One day the development of insulin pumps together with CGM could culminate in an artificial pancreas system. The performance of the glucose sensors used for glucose measurement in the interstitial fluid in the subcutaneous tissue and the algorithms employed to analyze these data have improved so much over the past decade that current CGM systems by far outperform those of the first generations. This commentary discusses a number of aspects about what we have learned since CGM systems entered the market and what current trends exist in their usage. Some of these are major hurdles facing a more widespread usage of CGM.

Keywords: artificial pancreas; continuous glucose monitoring; diabetes therapy; glucose sensors; hypoglycemia; quality of life.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: VL is an employee of Roche Diagnostics, Mannheim, Germany. BK is CEO of the Research Institute of the Diabetes Academy Mergentheim and member of the board and consultant for a number of companies developing novel diagnostic and therapeutic options for diabetes therapy. OS is consultant for companies developing novel approaches in diabetes technology. LH is shareholder of the Profil Institut für Stoffwechselforschung, Neuss, Germany, and Profil Institute for Clinical Research, San Diego, USA. LH is consultant for a number of companies that are developing novel diagnostic and therapeutic options for diabetes therapy.

References

    1. Heinemann L, Franc S, Phillip M, et al. Reimbursement for continuous glucose monitoring: a European view. J Diabetes Sci Technol. 2012;6:1498-1502. - PMC - PubMed
    1. Langendam MW, Luijf YM, Hooft L, DeVries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;1:CD008101. - PMC - PubMed
    1. JDRF. Randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther. 2008;10:310-321. - PubMed
    1. Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32:1378-1383. - PMC - PubMed
    1. Juvenile Diabetes Research Foundation, Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476. - PubMed